Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825324 | 0.81 | KCNH2 (0.40) | TOP2ATOP2B | |
| SCHEMBL29954963 | 0.79 | TOP2A (0.37) | TOP2ATOP2B | |
| SCHEMBL29955245 | 0.76 | KCNH2 (0.40) | TOP2ATOP2B | |
| SCHEMBL8785244 | 0.74 | TOP2A (0.39) | TOP2ATOP2B | |
| SCHEMBL8927420 | 0.73 | ADRB2 (0.51) | TOP2ATOP2B | |
| SCHEMBL5908567 | 0.68 | ALDH1A1 (0.43) | TOP2ATOP2B | |
| SCHEMBL29576548 | 0.68 | ALDH1A1 (0.43) | TOP2ATOP2B | |
| SCHEMBL28684693 | 0.66 | PTPN1 (0.40) | — | |
| SCHEMBL14752110 | 0.66 | KCNH2 (0.44) | TOP2ATOP2B | |
| SCHEMBL22774058 | 0.64 | ALDH1A1 (0.40) | TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569563-B2 | Substituted quinolones II | AICURIS GMBH & CO. HK (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20080261964-A1 | Substituted quinolones II | AICURIS GMBH & CO. KG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261964-A1 | Substituted quinolones II | TOP2A, TPMT, TOP2B | TOP2A 1/4885TOP2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.